Physician profile
Daniel J Hammer
NPI 1346575479
$8,698.23
in general payments reported to CMS, 2019-2025
25 companies · $3,852 in 2025
The $3,852 reported for 2025 was more than what 93% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $334 · 2021: $287 · 2022: $892 · 2023: $440 · 2024: $2,125 · 2025: $3,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Food and Beverage: $2,415 · Travel and Lodging: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Food and Beverage | $2,415.30 |
| Travel and Lodging | $1,001.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Haag-Streit USA, INC. | $3,000.00 | 2025 | |
| Axogen | $1,396.68 | 2024 | Axoguard Nerve Protector, Axoguard Nerve Connector, Avance Nerve Graft |
| Alcon Vision LLC | $1,061.72 | 2019-2025 | Hydrus Microstent, Clareon, Simbrinza |
| Abbvie INC. | $763.52 | 2022-2025 | |
| Allergan, INC. | $716.22 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $414.79 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $296.59 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Sun Pharmaceutical Industries INC. | $225.22 | 2019-2025 | Xelpros, Cequa |
| Thea Pharma INC. | $186.36 | 2024-2025 | Iyuzeh |
| Stryker Corporation | $92.73 | 2024 | Na |
| Novartis Pharmaceuticals Corporation | $81.78 | 2020-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $77.48 | 2023-2025 | Tecnis Simplicity, Tecnis Iol |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $71.17 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $60.38 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $48.44 | 2024 | Xdemvy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $39.13 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $33.26 | 2019-2023 | Omni Surgical System |
| Rxsight INC | $31.80 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| New World Medical,INC. | $25.56 | 2023-2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Biotissue Holdings INC. | $22.67 | 2022 | |
| Oculus Surgical INC. | $13.65 | 2024 | |
| Ivantis, INC | $13.17 | 2021 | |
| Spark Therapeutics, INC. | $12.68 | 2019 | |
| Horizon Therapeutics Plc | $11.54 | 2019 | |
| Lombart Brothers, INC. | $1.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.